Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Combined With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Used for the Advanced Slow-progressed Non Small Cell Lung Cancer Patients With EGFR-TKI Resistance

NCT03428022 is registered in ClinicalTrials.gov with Shenzhen People's Hospital as lead sponsor.

NCT NCT03428022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03428022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Combined With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Used for the Advanced Slow-progressed Non Small Cell Lung Cancer Patients With EGFR-TKI Resistance
Lead sponsor
Shenzhen People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
December 1, 2017
Completion date
December 31, 2020
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, egfr-tki, nsclc